ECS modulator (research)

CBD-DMHCannabidiol-dimethylheptyl

Synthetic CBD analogue with a dimethylheptyl chain, a mixed agonist and allosteric modulator of CB1 and CB2.

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

Receptors and activity

CB1Modulator45 out of 100
agoniste mixte et modulateur allostérique positif (Tham et coll., 2019)
CB2Modulator50 out of 100
liaison allostérique et orthostérique, agonisme partiel sur l'activation des protéines G (Bouma et coll., 2023)

Bar length shows the relative strength of the interaction, as an indication.

Subjective signature

Calm: 6 out of 100; Relaxation of body and mind; reduced mental noise without marked drowsiness.
Clarity: 4 out of 100; Sustained attention and clear thinking; functional lucidity, not euphoria.
High: 2 out of 100; Euphoria and sensory intensity; altered perception of time and space.
Appetite: 4 out of 100; Stimulation of hunger and of taste appreciation (the “munchies” effect).
Sleep: 4 out of 100; Sedative effect: aids sleep onset and the continuity of deep sleep.

Editorial estimate, not clinical.

Pharmacology

Cannabidiol-dimethylheptyl (CBD-DMH) is a synthetic analogue of cannabidiol carrying the 1,1-dimethylheptyl chain. Studied from the 1980s as an anticonvulsant more active than CBD, it was the subject in 1988 of a pharmacokinetic study in dogs: terminal half-life of 2 hours, clearance of 8.3 litres per hour and low, variable oral bioavailability, from 3 to 43 % in the animals where it was detectable. Its pharmacology diverges from that of CBD: in 2019 Tham and colleagues showed that it acts at CB1 as a mixed agonist and positive allosteric modulator, whereas CBD is a negative modulator there. In 2023 Bouma and colleagues described at CB2 a dual binding mode, allosteric and orthosteric, absent in cannabidiol. No human data exist.

Key sources.

History

Source: A fully synthetic molecule: an analogue of cannabidiol in which the pentyl chain is replaced by a 1,1-dimethylheptyl chain. It does not occur in hemp and serves only as a research tool.

Origin (research tool)

No biosynthetic pathway: the molecule comes from no living organism. It is obtained by organic synthesis, by coupling a resorcinol bearing a dimethylheptyl chain to the terpene fragment of cannabidiol.

Legal framework

European Union: No control measure of its own at European Union level. The molecule appears in no schedule of the 1961 Convention on Narcotic Drugs or of the 1971 Convention on Psychotropic Substances. It holds no marketing authorisation and no novel food authorisation under Regulation (EU) 2015/2283: it circulates only as a chemical or reference standard intended for research.
France: Unscheduled substance. CBD-DMH is named in no annex of the order of 22 February 1990 and falls under no generic clause: it is not a tetrahydrocannabinol and it lacks the benzo[c]chromene nucleus targeted by the ANSM decision of 22 May 2024, its open skeleton being that of cannabidiol. This absence of scheduling is not an authorisation: the molecule has no status as a medicine, food ingredient or cosmetic.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

References

Structured data

SMILES: CCCCCCC(C)(C)C1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O
InChIKey: MPJURNPNPDQYSY-LEWJYISDSA-N

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.